Nuvig Therapeutics vs Tempus
Side-by-side comparison of AI visibility scores, market position, and capabilities
Nuvig Therapeutics develops first-in-class Fc-fragment immunomodulators targeting endogenous regulatory pathways to treat autoimmune diseases without broad immune suppression.
About
Nuvig Therapeutics is a privately held biotechnology company developing next-generation immunomodulatory therapies for patients with chronic inflammatory and autoimmune diseases. Its lead candidate, NVG-2089, is a first-in-class recombinant Fc fragment engineered to bind type II Fc receptors and engage an endogenous regulatory mechanism that restores immune balance without the broad immunosuppression associated with existing treatments.
Publicly traded AI precision medicine company (Nasdaq: TEM); $1.27B revenue in 2025 (+83% YoY); $14B+ market cap; genomic profiling, algorithmic diagnostics, and clinical trial matching across oncology, neurology, and cardiology.
About
Tempus AI is a technology company applying artificial intelligence to advance precision medicine across oncology, neurology, psychiatry, and cardiology. Founded in 2015 by Eric Lefkofsky (co-founder of Groupon) and headquartered in Chicago, Illinois, Tempus built the world's largest library of clinical and molecular data and applies AI to help physicians make more personalized, data-driven treatment decisions. The company's core offerings include genomic profiling (sequencing tumor DNA to identify mutations and actionable targets), algorithmic diagnostic tests (AI-driven companion diagnostics for cancer treatment selection), clinical trial matching (connecting eligible patients to appropriate studies), and data licensing to pharmaceutical and biotech partners for drug discovery and clinical development.
AI Visibility Head-to-Head
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.